A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

AIMS: Ustekinumab (UST) has been shown to induce and maintain clinical response and remission in moderate-severe Crohn’s disease (CD) in 2 induction (UNITI-1 & 2) and 1 maintenance (IM-UNITI) randomized, PBO-controlled Phase 3 trials. We evaluated the efficacy of UST in 2 additional groups in IM...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Can Assoc Gastroenterol
Prif Awduron: Sands, B E, Gasink, C, Jacobstein, D, Gao, L, Johanns, J, Szapary, P, Colombel, J F, Targan, S, Ghosh, S, Sandborn, W
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2018
Pynciau:
Poster Presentations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507553/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.086
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg